English
Home > Products > Dolutegravir API

China Dolutegravir API Factory

Our mission is to become an innovative supplier of high-tech digital and communication devices by providing value added design, world-class manufacturing, and service capabilities for Dolutegravir API,CAS NO 1051375-16-6,1051375-16-6,Dolutegravir, We hope to establish far more organization associations with consumers all over the globe.
Dolutegravir API, With good quality, reasonable price and sincere service, we enjoy a good reputation. Items are exported to South America, Australia, Southeast Asia and so on. Warmly welcome customers at home and abroad to cooperate with us for the brilliant future.

Related Products

Hot Products

  • Vancomycin HCl Injection

    Vancomycin HCl Injection

    Product Name:Vancomycin HCl Injection
    Dosage:0.5g
    Application:Antibiotic
  • 2-Chloro-5-methylpyridine

    2-Chloro-5-methylpyridine

    Product Name:2-Chloro-5-methylpyridine
    Molecular Formula:C6H6ClN
    Molecular Weight:127.57
    CAS Registry Number:18368-64-4
  • Rutin

    Rutin

    Product Name:Rutin
    Molecular Formula:C27H30O163H2O
    Molecular Weight;664.56
    CAS Registry Number;250249-75-3
  • Pentafluorophenol

    Pentafluorophenol

    Product Name:Pentafluorophenol
    Molecular Formula:C6HF5O
    Molecular Weight:184.06
    CAS Registry Number:771-61-9
  • Nitazoxanide

    Nitazoxanide

    Product Name:Nitazoxanide
    Molecular Formula:C12H9N3O5S
    Molecular Weight;307.28
    CAS Registry Number;55981-09-4
  • Ceftizoxime sodium

    Ceftizoxime sodium

    Product Name:Ceftizoxime sodium
    Molecular Formula:C13H14N5NaO5S2
    Molecular Weight;407.39
    CAS Registry Number;68401-82-1
  • Related Blog
  • Reviews

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • How much do you know about minocycline hydrochloride?

    Minocycline hydrochloride is commonly used as its hydrochloride, which is yellow crystalline powder, odorless, bitter in taste, and can cause deterioration when exposed to light. Soluble in water, slightly soluble in ethanol, easily soluble in alkali metal hydroxide or carbonate solution.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept